

Synthesis, characterization of novel five-membered heterocycles and their anti-candidal activity

Rasim Farraj Muslim^{1,*}, Hiba Maher Tawfeeq², Obaid Hasan Abid³ and Mustafa Nadhim Owaid⁴

¹Department of Ecology, College of Applied Sciences, University Of Anbar, Anbar 31007, Iraq

²Department of Chemistry, College of Education for Pure Sciences, University Of Anbar, Anbar 31001, Iraq

³Department of Scientific Affairs and Graduate Studies, University of Fallujah, Anbar, Iraq

⁴Department of Heet Education, General Directorate of Education in Anbar, Ministry of Education, Anbar 31007, Iraq

(* Corresponding author's e-mail: dr.rasim92hmts@gmail.com)

ABSTRACT


This research includes synthesis of new heterocyclic containing disubstituted tetrazol derivatives. Imine compounds were synthesized by reaction of aromatic aldehydes with primary aromatic amines, which reacted with various substituted benzaldehydes in the presence of a glacial acetic acid as catalyst in absolute ethanol to obtain new imine compounds O₁-O₅. The new tetrazol derivatives O₆-O₁₀ were obtained from treatment of each new imine compounds with sodium azide compound. Newly synthesized compounds were identified via spectral methods (FT-IR, ¹H-NMR and ¹³C-NMR) and some physical properties. O₆ is the best derivative that has significantly ($p < 0.01$) recorded a stronger influence to inhibit the growth of *Candida guilliermondii* at an average of the zone of inhibition 14.0 mm. While, O₉ derivative recorded the lowest zone of inhibition 7.3 mm toward the same clinical fungal pathogen. The present work may be helpful in designing more potential antibacterial and antifungal agents for therapeutic use in the future.

Keywords: tetrazol, *Candida* sp., anti-Candidal, imine compounds, pharmaceutical, sodium azide.

1. Introduction


Imine compounds are class of the compounds which contain the group (-HC=N-) (**Scheme 1**), They are usually synthesizing by the condensation of a primary aromatic amino group with an active carbonyl aromatic aldehyde, they are versatile precursors in the synthesis of organic, bio-organic, organometallic and industrial compounds via ring closure, cycloaddition and replacement reactions.¹⁻⁴ Imine compounds were discovered by a German chemist, Nobel prize

8 winner, Hugo Schiff in 1864.⁵ Imine compounds produced from the reaction between ketone or
 9 aldehyde compounds with amine compounds.⁶




11 **Scheme 1.** Structure of imine compounds

12 In the presence of perchloric acid (**Scheme 2**) the reaction of 4-fluorobenzaldehyde with 1-
 13 benzylpiperidin-4-amine gave the next product.⁷




15 **Scheme 2.** The effect of perchloric acid on imine compound formation

17 The reaction of pyridine-2-amine with 4-(dimethyl amino) benzaldehyde (**Scheme 3**)
 18 produces the imine compound.⁸



20 **Scheme 3.** Using glacial acetic acid to prepare the imine compound


22 One of the most important chemical compounds is sodium azide, which has been used in
 23 many fields including its effect on germination.⁹ Due to its great importance, it was used in the
 24 preparation of compounds called tetrazoles. Tetrazoles are a class of synthetic organic
 25 heterocyclic compounds consist of five-member ring of four nitrogen atoms and one carbon atom
 26 (**Scheme 4**).¹⁰



28 **Scheme 4.** Structure of tetrazol ring


30 Synthesis of tetrazol derivatives is an important task in modern medicinal chemistry.¹¹
 31 Tetrazoles are class of heterocycles that have received attention due to their wide range of
 32 applications.¹² Pharmacologically, because of the effect of gram-negative or positive bacteria on
 33 the health of human. Then they must synthesize some products which have anti-activity against
 34 bacteria.^{13,14} Tetrazole contains compounds reported to possess diverse chemotherapeutic

activities as antibacterial,¹⁵ and antifungal.¹⁶ Example of one of tetrazol derivatives is the product from the reaction between imine compound (N,N'-([1,1'-biphenyl]-4,4'-diyl) bis (1-(pyridine-4-yl)methanimine)) and sodium azide (Scheme 5).¹⁷



Scheme 5. Synthesized of 2,5-dihydro-1H-tetrazol derivative

Tetrazol derivatives of type of 5-phenyl-1H-tetrazol-1-yl) thiazetidine dioxide prepared from the next reaction (Scheme 6),¹⁸ below:



Scheme 6. Potassium carbonate in tetrazol derivatives synthesis






2. Experimental

2. 1. General procedure for the synthesis of imine compounds O₁-O₅

Equimolar mixtures 0.02 mol, of aldehydes and aromatic amines and trace of glacial acetic acid dissolved in 25 ml absolute ethanol was placed in a 100-ml round-bottom flask equipped with condenser and stirrer bar. The mixture was allowed to react at reflux temperature for 4hr, then allowed to cool down to the room temperature, whereby a crystalline solid was separated out. The solid product was recrystallized twice from ethanol.¹⁹⁻²¹ The structural formulae, names, melting points, colors, and percentage of yields for the synthesized imine compounds are recorded in table 1.

Table 1. Structural formula, nomenclature, melting points, percentages of yield and colors of imine compounds O₁-O₅

Comp.	Structural formula	Nomenclature	Yield	m.p.	Color
-------	--------------------	--------------	-------	------	-------






Code			%	°C	
O ₁		(E)-5-((4,6-dimethylpyrimidin-2-ylimino)methyl)-2-methoxyphenol	68%	78-80	Tan
O ₂		(E)-1-(2,4-dinitrophenyl)-2-(4-nitrobenzylidene)hydrazine	81%	291-293	Orange
O ₃		(E)-4-(4-ethoxybenzylideneamino)-1,5-dimethyl-2-phenyl-1H-pyrazol-3(2H)-one	90%	212-214	Bright yellow
O ₄		4-(5-chloro-2-hydroxybenzylideneamino)-1,5-dimethyl-2-phenyl-1H-pyrazol-3(2H)-one	89%	138-140	Bright pale yellow
O ₅		(E)-2-((p-tolylimino)methyl)phenol	87%	94-96	Bright yellow

2. 2. General procedure for the synthesis of tetrazol derivatives O₆-O₁₀

Equimolar mixtures 0.01 mol, of imine compounds and sodium azide dissolved in 20 ml of tetrahydrofuran and 2 ml of distilled water and refluxed the mixture for 4hr and left to stand for 24hr. The solid product was precipitated, filtered off and recrystallized from ethanol.^{22,23} The structural formulae, names, melting points, colors, and percentage yields for the synthesized tetrazol derivatives are presented in table 2. Melting points were recorded on electrothermal melting point apparatus (uncorrected). FT-IR spectra were recorded at the room temperature from (4000-400) cm⁻¹ with KBr disc by infrared spectrophotometer model tensor 27 Bruker Co., Germany. The ¹H-NMR and ¹³C-NMR spectra were recorded by Bruker Ac-300MHz spectrometer, see table 2.

Table 2. Structural formula, nomenclature, melting points, percentages of yield and colors of tetrazol derivatives O₆-O₁₀

Comp. code	Structural formula	Nomenclature	Yield %	m.p. °C	Color
------------	--------------------	--------------	---------	---------	-------

O ₆		5-(1-(4,6-dimethylpyrimidin-2-yl)-4,5-dihydro-1H-tetrazol-5-yl)-2-methoxy phenol	81%	107-109	Bright Pale yellow
O ₇		N-(2,4-dinitrophenyl)-5-(4-nitrophenyl)-4,5-dihydro-1H-tetrazol-1-amine	89%	> 300	Pale Orange
O ₈		5-(4-chlorophenyl)-4-(1,5-dimethyl-3-oxo-2-phenyl-2,3-dihydro-1H-pyrazol-4-yl)-4,5-dihydro-1H-tetrazol-1-ide	93%	242-244	Pale yellow
O ₉		4-(5-(5-chloro-2-hydroxyphenyl)-4,5-dihydro-1H-tetrazol-1-yl)-1,5-dimethyl-2-phenyl-1H-pyrazol-3(2H)-one	85%	169-171	Pale yellow
O ₁₀		R)-2-(1-p-tolyl-4,5-dihydro-1H-tetrazol-5-yl)phenol	84%	119-120	Bright Golden

2. 3. Anti-Candidal activity

This test was archived *in vitro* to investigate inhibitory effects of the synthesized tetrazol derivatives using well diffusion method on Muller-Hinton agar. This experiment was done as mentioned by Owaid et al.²⁴ Four milligrams of the synthesized tetrazol derivatives were applied separately in 6 mm-well. After 18 hr of incubation at 37 °C, the zone of inhibition was taken using the ruler in millimeters.

2. 4. Statistical Analysis


The data (triplicates) were analyzed by one-way analysis of variance using ANOVA table by SAS program for Windows, version 9.0, SAS Institute Inc., USA. The significance of differences was calculated using Duncan's Multiple Range Test (DMRT). Probability value least than 1% was considered to be statistically significant.

3. Results and discussion

3. 1. Imine compounds

Imine compounds (Scheme 7) were synthesized from commercially available aromatic aldehydes and primary amines and identified by their melting points, and FT-IR. The FT-IR

98 spectra showed the appearance of the stretching absorption bands of azomethine (C=N) at 1591-
99 1669 cm⁻¹,^{25,26} beside the characteristic bands of the residual groups in the structure table 3. See
100 Figs. 1 and 2.



103 **Scheme 7.** Structure of the synthesized imine compounds

105 **Table 3.** FT-IR spectra of imine compounds O₁-O₅

Comp. Code	FT-IR, $\nu(\text{cm}^{-1})$						Others
	C=N	C=C	C-H		C-H Ali.		
		Aromatic	Aromatic	Alkene	Asymmetric	symmetric	
O₁	1669	1510	3000	3045	2974	2941	O-H b3309, C=N yrimidine1547
O₂	1610	1572	3042	3089	--	--	NO ₂ 1505, 1322 N-H 3277
O₃	1591	1569	3044	3067	2983	2875	C=O 1645, C-Cl 829
O₄	1594	1559	3044	3075	2983	2874	C=O 1634, C-Cl 815 O-H b3450
O₅	1614	1566	3046	3079	2980	2867	O-H b3375

107




Fig. 1. FT-IR spectra of O_1





Fig. 2. FT-IR spectra of O_2

Mechanism of imine compounds formation represented in the following reaction.^{27,28} See scheme 8.



Scheme 8. Mechanism of imine compounds formation

3. 2. Tetrazol derivatives

The synthesis of tetrazol derivatives was achieved by the reaction of imine and sodium azide. Their melting points identified the resulted products. FT-IR spectra of the products (table 4) showed characteristic absorption band at 1272-1301, 1022-1089 and 1484-1509 cm^{-1} as an indicative of C-N, N-N and N=N bonds of tetrazol rings formation beside the characteristic bands of the residual groups in the structure as presented in Figs. 3 and 4.²⁶

Table 4. FT-IR spectra of tetrazol derivatives O₆-O₁₀

Comp. code	FT-IR $\nu(\text{cm}^{-1})$								Others
	N-H	N-N	N=N	C-N	C=C	C-H	C-H Ali.		
					Aromatic	Aromatic	Asymmetric	Symmetric	
O ₆	3229	1022	1512	1278	1578	3082	2937	2875	O-H b 3627
O ₇	3279	1089	1509	1272	1594	3091	2968	2877	NO ₂ 1575,1331
O ₈	--	1086	1484	1301	1594	3060	2941	2865	C=O 1650
									C-Cl 768
									O-H b 3491
O ₉	3280	1087	1484	1273	1564	3055	2954	2874	C=O1638
O ₁₀	3320	1033	1499	1283	1598	3053	2920	2855	C-Cl 772
									O-H b 3446




Fig. 3. FT-IR spectra of O₆




Fig. 4. FT-IR spectra of O₇


The ¹H-NMR spectrum of compound O₈ in DMSO solvent (Fig. 5) showed chemical shifts, δ(ppm), singlet in 2.46 (3H, N-CH₃), singlet in 3.20 (3H, =C-CH₃), singlet in 9.57 (1H, N-CH), multiplet and doublet of doublet in 7.85-7.36 (9H, aromatic protons). Spectrum of compound O₉ (Fig. 6) showed chemical shifts, δ(ppm) at: singlet in 2.42 (3H, N-CH₃), singlet in 3.23 (3H, =C-CH₃), singlet in 6.78 (1H, -NH), singlet in 9.67 (1H, N-CH), singlet in 12.73 (1H, -OH),

136 multiplet in 7.64-6.93 (8H, aromatic protons).²⁹ Other chemical shifts of O₆, O₇ and O₁₀, δ(ppm)
137 are presented in table 5.

138 **Table 5.** The ¹H-NMR Spectra of tetrazol derivatives O₆-O₁₀ in DMSO

Comp. code	Chemical Shift δ ppm
O ₆	Singlet in 2.40 (6H, 2 <u>CH</u> ₃), singlet in 3.34 (3H, O- <u>CH</u> ₃), singlet in 7.11 (1H, - <u>NH</u>), singlet in 9.58 (1H, N- <u>CH</u>), singlet in 9.77 (1H, - <u>OH</u>), multiplet and singlet in 7.42- 7.11 (4H, aromatic protons)
O ₇	Singlet in 3.57 (1H, <u>NH out</u>), singlet in 8.89 (1H, <u>NH in</u>), singlet in 11.86 (1H, N- <u>CH</u>) and multiplet and doublet of doublet in 8.82-8.05 (7H,aromatic protons)
O ₈	Singlet in 2.46 (3H, N- <u>CH</u> ₃), singlet in 3.20 (3H, =C- <u>CH</u> ₃), singlet in 9.57 (1H, N- <u>CH</u>), multiplet and doublet of doublet in 7.85-7.36 (9H, aromatic protons)
O ₉	Singlet in 2.42 (3H, N- <u>CH</u> ₃), singlet in 3.23 (3H, =C- <u>CH</u> ₃), singlet in 6.78 (1H, - <u>NH</u>), singlet in 9.67 (1H, N- <u>CH</u>), singlet in 12.73 (1H, - <u>OH</u>), multiplet in 7.64-6.93 (8H, aromatic protons)
O ₁₀	Singlet in 2.34 (3H, <u>CH</u> ₃), singlet in 6.80 (1H, - <u>NH</u>), singlet in 8.67 (H, N- <u>CH</u>), singlet in 13.25 (1H, - <u>OH</u>), multiplet and doublet of doublet in 7.66-6.95 (8H, aromatic protons)

139
140



141

Fig. 5. ¹H-NMR Spectra of O₈




Fig. 6. ¹H-NMR Spectra of O₉

The ¹³C-NMR spectrum of compound O₆ in DMSO solvent (Fig. 7) showed chemical shifts, δ(ppm), 37.47 (2 CH₃), 56.27 (O-CH₃), 191.91 (N-CH), 112.04-124.94 (Aromatic Carbons), 130.29-153.80 (Pyrimidine Carbons). While the spectrum of compound O₉ (Fig. 8) exhibited chemical shifts, δ(ppm), 9.79 (N-CH₃), 35.01 (=C-CH₃), 150.46 (CH₃-C=), 154.78 (CO-C=), 157.80 (N-CH), 158.59 (N-CO), 113.96-134.10 (Aromatic Carbons).³⁰ Other chemical Shifts of O₇, O₈, O₁₀, δ(ppm) are displayed in table 6.

Table 6. The ¹³C-NMR spectra of tetrazol derivatives O₆-O₁₀ in DMSO

Comp. code	Chemical Shift δ ppm
O ₆	37.47 (2 <u>CH</u> ₃), 56.27 (O- <u>CH</u> ₃), 191.91 (N- <u>CH</u>), 112.04-124.94 (Aromatic Carbons), 130.29-153.80 (Pyrimidine Carbons)
O ₇	182.49 (N- <u>CH</u>), 118.96-125.56 (Aromatic Carbons)
O ₈	10.33 (N- <u>CH</u> ₃), 35.83 (=C- <u>CH</u> ₃), 144.11 (CH ₃ - <u>C</u> =), 152.34 (CO- <u>C</u> =), 159.99 (N- <u>CH</u>), 162.47 (N- <u>CO</u>), 115.08-128.22 (Aromatic Carbons)
O ₉	9.79 (N- <u>CH</u> ₃), 35.01 (=C- <u>CH</u> ₃), 150.46 (CH ₃ - <u>C</u> =), 154.78 (CO- <u>C</u> =), 157.80 (N- <u>CH</u>), 158.59 (N- <u>CO</u>), 113.96-134.10 (Aromatic Carbons)



Fig. 7. ^{13}C -NMR Spectra of O_6

The results of FT-IR ^{13}C -NMR and ^1H -NMR showed that the five-ringed compounds were the least obstructed in all preparation processes. Because of the complete clarity in infrared beams and clear signals separated from each another by the resonance spectrum nuclear magnetic of hydrogen and carbon, this is the basis of organic preparation processes.

3. 3. Anti-Candidal activity

Zone of inhibition of some human pathogenic fungi was done well-diffusion method to test the potential of the tetrazol derivatives O_6 - O_{10} as shown in Figs. 8 and 9. O_6 is the best derivative that has significantly ($p < 0.01$) recorded a stronger influence to inhibit the growth of *Candida guilliermondii* at an average of the zone of inhibition 14.0 mm. While, O_9 derivative recorded the lowest zone of inhibition 7.3 mm toward the same clinical fungal pathogen. From another hand, O_6 showed zone of inhibition 12.0 mm against *Candida zeylanoides*. Furthermore, O_6 derivative recorded zone of inhibition 11.3 mm against *Candida krusei* and *Candida abicans*. O_{10} did not inhibit the growth of *Candida albicans* as shown in Fig. 9. The resistance mechanisms depend on which specific pathways are inhibited by the drugs and the alternative ways available for those pathways that the organisms can modify to get a way around to survive.³² Also, the synthesis heterocyclic compounds is useful against various pathogens such as viruses.^{33,34} Many new metal complexes and new 1,3-oxazepine derivatives had good antibacterial activity.^{35,36} Tetrazol derivatives are important to synthesize inflammatory agents.³⁷




Fig. 8. Zone of inhibition of *Candida* sp. using the synthesized tetrazole derivatives O_6 - O_{10}




Fig. 9. Anti-Candidal activity of the synthesized tetrazole derivatives O₆-O₁₀

4. Conclusion

Preparing derivatives of tetrazol was possible. The results of FT-IR, ¹³C-NMR and ¹H-NMR showed that the five-ringed compounds were the least obstructed in all preparation processes. Because of the complete clarity in infrared beams and clear signals separated from each another by the resonance spectrum nuclear magnetic of hydrogen and carbon, this is the basis of organic preparation processes. O₆ is the best derivative that has significantly ($p < 0.01$) recorded a stronger influence to inhibit the growth of *Candida guilliermondii* at an average of the zone of inhibition 14.0 mm. While, O₉ derivative recorded the lowest zone of inhibition 7.3 mm toward the same clinical fungal pathogen. The present work may be helpful in designing more potential antibacterial and antifungal agents for therapeutic use in the future.

5. Acknowledgment

Special thanks to Anbar University's President Professor Dr. Khalid Battal Najim for his continuous support to publishing the research in certified international journals. Also, grateful is for Dr. Abdullah Hussein Kshash, Department of Chemistry, College of Education for Pure Sciences, University Of Anbar for helping to measurement the FT-IR spectra.

6. REFERENCES

214 1. A. Adabiardakani, M. Hakimi, H. Kargar, *WA P journal*. **2012**, 2, 472–476.

215 2. K. Brodowska, E. Chruścińska, *CHEMIK*. **2014**, 68, 129–134.

216 3. W. Qin, S. Long, M. Panunzio, S. Biondi, *Molecules*. **2013**, 18, 12264–12289.

217 4. O. Abid, R. Muslim, K. Mohammed, *J. Uni. Al-Anbar Pure Sci*. **2016**, 10, 8–18.

218 5. M. Ashraf, K. Mahmood, A. Wajid, *IPCBEE*. **2011**, 10, 1–7.

219 6. Z. Hussain, Z. Fadhil, H. Adil, M. Khalaf, B. Abdullah, E. Yousif, *RJPBCS*. **2016**, 7, 1500–1510.

220 7. P. Mayavel, K. Thirumurthy, S. Dineshkumar, G. Thirunarayanan, *Umcschem. Ixix* **2014**, 159–179.

221 8. N. Al-Jamali, M. Jameel, A. Al-Haidari, *Innovare Journal of Science*. **2013**, 1, 13–15.

222 9. M. Dahot, E. Rind and M. Rafiq, *Pak. J. Biotechnol.* **2011**, 8, 67–72.

223 10. J. Mohammed, *DRJI*. **2016**, 3, 12796–12804.

224 11. D. Varadarasi, S. Suban, V. Ramasamy, K. Kubendirran J. Raguraman, S. Nalilu, H. Pati,

225 *Organic Communications*. **2010**, 3, 45–56.

226 12. K. Babu, V. Prabhakar, L. Ravindranath, N. Kishore, J. Latha, *Res. J. Chem. Environ. Sci.* **2016**,

227 4, 51–63.

228 13. Z. Al-Hakak, *Pak. J. Biotechnol.* **2017**, 14, 417–422.

229 14. N. Sial, S. Abro, J. Shah, M. Memon, *Pak. J. Biotechnol.* **2016**, 1, 67–71.

230 15. W. El-Sayed, R. Abdel Megeid, H. Abbas, *Arch. Pharm. Res.*, **2011**, 34, 1085–1096.

231 16. M. Malik and S. Al-Thabaiti, *Int. J. Mol. Sci.* **2012**, 13, 10880–10898.

232 17. R. Al-Juburi, *Journal of Al-Nahrain University*. **2012**, 15, 60–67.

233 18. P. Babu, L. Ravindranath, D. Rajesh, B. Saritha, *World Journal of Pharmacy and Pharmaceutical*

234 *Sciences*. **2016**, 5, 929–940.

235 19. O. Abid, H. Tawfeeq, R. Muslim, *Acta Pharm. Sci.* **2017**, 55, 43–55. DOI: 10.23893/1307-

236 2080.APS.05525

237 20. M. Murhekar and R. Khadsan, *J. Chem. Pharm. Res.* **2011**, 3, 846–849.

238 21. H. Sabah, *Der Pharma Chemica*. **2014**, 6, 38–41.

239 22. B. Srinivas, B. Prasanna, M. Ravinder, *Der Pharma Chemica*. **2016**, 8, 84–93.

240 23. P. Ravula, H. Vamaraju, M. Paturi, N. Chandra, S. Kolli, *EXCLI Journal*. **2016**, 15, 187–202.

241 24. M. Owaid, J. Raman, H. Lakshmanan, S. Al-Saeedi, V. Sabaratnam, I. Al-Assaffii, *Mater. Lett.*

242 **2015**, 153, 186–190. DOI: 10.1016/j.matlet.2015.04.023

243 25. R. Muslim, H. Tawfeeq, M.N. Owaid, O. Abid, *Acta Pharmaceutica Scientia* **2018**, 56, 39–57. DOI:

244 10.1248/bpb.b15-00698

245 26. R. Silverstein, F. Webster, D. Kiemle, *Spectrometric identification of organic compounds*, 7th

246 edition, John Wiley and sons, Inc., **2005**, 72–126.

- 247 27. J. Simek, Organic Chemistry, 8th edition, Pearson education, Inc., **2013**, 412–414.
- 248 28. O. Abid, R. Muslim, K. Mohammed, *J. Uni. Anbar Pure Sci.* **2016**, 10, 1–9.
- 249 29. R. Silverstein, F. Webster, D. Kiemle, Spectrometric identification of organic compounds, 7th
- 250 edition, John Wiley and sons, Inc., **2005**, 127–202.
- 251 30. B. Mistry, A Handbook of spectroscopic Data chemistry, edition 2009, Oxford book company
- 252 Jaipor India, Mehra Offset Printers, Delhi, **2009**, 99–127.
- 253 31. R. Das, N. Majumdar, A. Lahiri, *IJRPC*. **2014**, 4, 467–472.
- 254 32. F. Tenover, *Am. J. Med.* **2006**, 119, 3–10.
- 255 33. M. F. El Shehry, J. Balzarini, C. Meier, *Synthesis*. **2009**, 5, 841–847. DOI:10.1055/s-0028-
- 256 1083369
- 257 34. M. F. El Shehry, E. M. El Telbani, M. I. Hegab, *Acta Chim. Slov.* **2018**, 65, 401–406. DOI:
- 258 10.17344/acsi.2017.4144
- 259 35. R. Ahmed, I. Majeed, A. Ahmed, E. Yousif., M. Al-Jeboori, *Chem Xpress*. **2016**, 9(1), 61-68.
- 260 36. I. Jassim, I. Majeed, G. Al-Somaidaie, *Tikrit Journal of pharmaceutical Sciences*. **2009**, 5(2),
- 261 147-155.
- 262 37. M. F. El Shehry, A. A. Abu-Hashem, E. M. El-Telbani. *European Journal of Medicinal*
- 263 *Chemistry* **2010**, 45(5), 1906-1911.